Intratumoural delivery of SLR14 agonist provoked an effective antitumour response in both immunogenic (YMR 1.7) and poorly immunogenic (B16F10) melanoma mouse models by activating the cytosolic RIG-I pathway in different cell populations, i.e., tumour cells and non-tumour cells [66]. This evidence concerns the gene RIGI and melanoma.